IP Verse

Modulation Of Ube3A-Ats Expression - EP2864479

The patent EP2864479 was granted to Baylor College OF Medicine on Aug 15, 2018. The application was originally filed on Jun 25, 2013 under application number EP13809694A. The patent is currently recorded with a legal status of "Revoked".

EP2864479

BAYLOR COLLEGE OF MEDICINE
Application Number
EP13809694A
Filing Date
Jun 25, 2013
Status
Revoked
Jan 18, 2025
Grant Date
Aug 15, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

F HOFFMANN LA ROCHEMay 14, 2019D YOUNG -

Patent Citations (78) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20020399998-
DESCRIPTIONUS20070989574-
DESCRIPTIONUS20080026998-
DESCRIPTIONUS20080099844-
DESCRIPTIONWO2003US33466-
DESCRIPTIONWO2005US19219-
DESCRIPTIONUS2004171570
DESCRIPTIONUS2005130923
DESCRIPTIONUS2008039618
DESCRIPTIONUS2009012281
DESCRIPTIONUS4981957
DESCRIPTIONUS5034506
DESCRIPTIONUS5118800
DESCRIPTIONUS5166315
DESCRIPTIONUS5185444
DESCRIPTIONUS5319080
DESCRIPTIONUS5359044
DESCRIPTIONUS5393878
DESCRIPTIONUS5446137
DESCRIPTIONUS5466786
DESCRIPTIONUS5514785
DESCRIPTIONUS5519134
DESCRIPTIONUS5567811
DESCRIPTIONUS5576427
DESCRIPTIONUS5591722
DESCRIPTIONUS5597909
DESCRIPTIONUS5610300
DESCRIPTIONUS5627053
DESCRIPTIONUS5639873
DESCRIPTIONUS5646265
DESCRIPTIONUS5670633
DESCRIPTIONUS5698685
DESCRIPTIONUS5700920
DESCRIPTIONUS5792847
DESCRIPTIONUS6268490
DESCRIPTIONUS6525191
DESCRIPTIONUS6600032
DESCRIPTIONUS6670461
DESCRIPTIONUS6673661
DESCRIPTIONUS6770748
DESCRIPTIONUS6794499
DESCRIPTIONUS7034133
DESCRIPTIONUS7053207
DESCRIPTIONUS7399845
DESCRIPTIONUS7427672
DESCRIPTIONUS7547684
DESCRIPTIONUS7696345
DESCRIPTIONWO0063364
DESCRIPTIONWO0149687
DESCRIPTIONWO03004602
DESCRIPTIONWO2004106356
DESCRIPTIONWO2005021570
DESCRIPTIONWO2005121371
DESCRIPTIONWO2006047842
DESCRIPTIONWO2007134181
DESCRIPTIONWO2008101157
DESCRIPTIONWO2008150729
DESCRIPTIONWO2008154401
DESCRIPTIONWO2009006478
DESCRIPTIONWO2010036696
DESCRIPTIONWO2011139702
DESCRIPTIONWO2012012467
DESCRIPTIONWO2012064806
DESCRIPTIONWO9414226
DESCRIPTIONWO9839352
DESCRIPTIONWO9914226
INTERNATIONAL-SEARCH-REPORTWO0192582
INTERNATIONAL-SEARCH-REPORTWO2011109398
INTERNATIONAL-SEARCH-REPORTWO2012064806
OPPOSITIONUS2003087855
OPPOSITIONUS6184212
OPPOSITIONUS6300132
OPPOSITIONUS6617162
OPPOSITIONWO2004016754
OPPOSITIONWO2007087113
OPPOSITIONWO2012012467
OPPOSITIONWO2012064806
SEARCHWO2012012467

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- KOCH, T. et al., "Quantum Mechanical Studies of DNA and LNA", Nucleic Acid Therapeutics, (20140000), vol. 24, no. 2, pages 139 - 148, XP055366884-
OPPOSITION- SWAYZE, E., "Chapter 6. The medicinal chemistry of oligonucleotides", Antisense Drug Technology second edition, (20080101), pages 143 - 182, XP055467260-
OPPOSITION- LUO, W. et al., "A ribonucleolytic rat torpedoes RNA polymerase II", Cell, (20040000), vol. 119, pages 911 - 914, XP002540641
OPPOSITION- WAHLESTEDT, C., "Natural antisense and noncoding RNA transcripts as potential drug targets", Drug Discovery Today, (20060000), vol. 11, no. 11/12, pages 503 - 508, XP005436425
OPPOSITION- HAGEDORN, P. et al., "Locked nucleic acid: modality, diversity, and drug discovery", Drug Discovery Today, (20180000), vol. 23, no. 1, pages 101 - 114, XP055461215
OPPOSITION- HUANG, H-S. et al., "Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons", Nature, (20120000), vol. 481, no. 7380, pages 185 - 189, XP055266025
OPPOSITION- BEAUDET, A., "Drugs to awaken a paternal gene", Nature, (20120000), vol. 481, no. 7380, pages 150 - 152, XP055592443
OPPOSITION- Modarresi et al., "Supporting Online Materials Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation; Suppl. Information", Nature Biotechnology, (20120000), vol. 30, no. 5, pages 1 - 32, XP055223194
OPPOSITION- MODARRESI, F. et al., "Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation", Nature Biotechnology, (20120000), vol. 30, no. 5, pages 453 - 459, XP055052745
OPPOSITION- ROUGEULLE, C. et al., "An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript.", Nature Genetics, (19980000), vol. 19, pages 15 - 16, XP055592429
OPPOSITION- FAGHIHI, M. et al., "Regulatory roles of natural antisense transcripts", NIH Public Access Author Manuscript, (20090000), vol. 10, no. 9, pages 1 - 17, XP055592508
OPPOSITION- DANCKWARDT, S. et al., "Focus Quality Control 3' end mRNA processing: molecular mechanisms and implications for health and disease", The EMBO Journal, (20080206), vol. 27, pages 482 - 498, XP055592476
OPPOSITION- MENG, L. et al., "Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a", Hum Mol Genet, (20120000), vol. 21, no. 13, pages 3001 - 3012, XP055266008
OPPOSITION- EFTHYMIOU, A. et al., "Functional screening assays with neurons generated from pluripotent stem cell-derived neural stem cells", J Biomol Screen, (20140000), vol. 19, no. 1, pages 32 - 43, XP055340253
OPPOSITION- MORRIS, K. et al., "Bidirectional Transcription Directs Both Transcriptional Gene Activation and Suppression in Human Cells", PLoS Genetics, (20080000), vol. 4, no. 11, pages 1 - 9, XP055008804
OPPOSITION- FAGHIHI, "RNAi Screen Indicates Widespread Biological Function for Human Natural Antisense Transcripts", PLoS One, (20100000), vol. 5, no. 10, pages 1 - 10, XP055592454
OPPOSITION- CHAMBERLAIN, S. et al., "Angelman Syndrome, a Genomic Imprinting Disorderof the Brain", The Journal of Neuroscience, (20100000), vol. 30, no. 30, pages 9958 - 9963, XP055592458
SEARCH- HSIEN-SUNG HUANG ET AL, "Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons", NATURE, United Kingdom, (20111221), vol. 481, no. 7380, doi:10.1038/nature10726, ISSN 0028-0836, pages 185 - 189, XP055266025 [YD] 1-15 * the whole document *
SEARCH- ARTHUR L. BEAUDET, "Angelman syndrome: Drugs to awaken a paternal gene", NATURE, United Kingdom, (20111221), doi:10.1038/nature10784, ISSN 0028-0836, XP055266012 [A] 1-15 * the whole document *
SEARCH- LINYAN MENG ET AL, "Towards a therapy for Angelman syndrome by targeting a long non-coding RNA", NATURE, United Kingdom, (20141201), vol. 518, no. 7539, doi:10.1038/nature13975, ISSN 0028-0836, pages 409 - 412, XP055265928 [T] * the whole document *
SEARCH- L. MENG ET AL, "Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a", HUMAN MOLECULAR GENETICS, gb, (20120405), vol. 21, no. 13, doi:10.1093/hmg/dds130, ISSN 0964-6906, pages 3001 - 3012, XP055266008 [Y] 1-15 * the whole document *
SEARCH- LINYAN MENG ET AL, "Truncation of Ube3a-ATS Unsilences Paternal Ube3a and Ameliorates Behavioral Defects in the Angelman Syndrome Mouse Model", PLOS GENETICS, (20131226), vol. 9, no. 12, doi:10.1371/journal.pgen.1004039, page e1004039, XP055266009 [T] * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents